No intervention (observational study)
OtherNo intervention (observational study)
NCT Number: NCT07148193
The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Technical University Dresden, Dresden, Saxony, Germany
Sarcomas are rare cancers that can arise almost anywhere in the body and account for only about one percent of all cancer diagnoses. Both the disease and its treatments often result in late effects, yet knowledge about these long-term consequences remains limited. The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. Particular focus is placed on subgroups with potential long-term risks, including survivors of bone sarcomas, extremity or trunk sarcomas after multimodal treatment, retroperitoneal sarcomas, gastrointestinal stromal tumors (GIST) with or without long-term TKI therapy, and young adult survivors.
The mixed-methods research design includes a multicenter observational study with a one-time questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.
Recruitment is built on draws on existing network structures, including the PROSa cohort, the National Center for Tumor Diseases (NCT/UCC) Dresden, the SarcBOP registry at the National Center for Tumor Diseases (NCT) Heidelberg, West German Cancer Center Essen (WTZ), University Hospital Mannheim (UMM), the German Sarcoma Foundation, and cooperating sarcoma centers. Medical data are extracted from patient records.
Statistical analyses will include descriptive statistics and regression models to identify impaired quality of life domains and associated factors.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention (observational study)
Time frame: single-time point (enrollment)
The EORTC QLQ-SURV100 is a 100-item questionnaire assessing general quality of life among cancer survivors. It includes multiple functional scales covering physical, role, emotional, cognitive, and social functioning, as well as symptom scales (fatigue, pain) and several single-item measures. Most items are rated on a 1-4 scale, while two global items on overall quality of life and general health are rated on a 1-7 scale. Higher scores on the functional and global health status scales indicate better quality of life, whereas higher scores on symptom scales reflect worse quality of life.
With the exception of five acute symptoms, the SURV100 includes all items from the EORTC QLQ-C30. To enable comparative analyses, the investigators supplemented the SURV100 with these five missing items: appetite loss, nausea, vomiting, constipation, and diarrhea.
Time frame: single time point (enrollment)
Satisfaction with medical care and communication will be assessed using three items adapted from the EORTC OUT-PATSAT7 and three self-developed items, all rated on a 1-5 scale. Higher scores indicate greater satisfaction with the medical care received.
Time frame: single time point (enrollment)
Service utilization will be assessed with self-developed items based on the Cancer Survivors' Unmet Needs measure (CaSUN). Participants indicate their use of 24 different non-rehabilitation care services and 11 rehabilitation care services. Response options include two types of "No" (offer not available or offer available but not used) and, if "Yes," a rating from 1-3 indicating how helpful the offer was, with higher scores reflecting greater helpfulness.
Time frame: single time point (enrollment)
Unmet needs will be assessed with self-developed items based on the CaSUN, asking participants about the lack of adequate support or services in 20 areas. Response options include two types of "No" (no need or need has already been met) and, if "Yes," a rating from 1-3 indicating the current intensity of the unmet need, with higher scores reflecting greater unmet need.
Time frame: single-time point (enrollment)
Fatigue will be assessed using the 12-item EORTC QLQ-FA12 scale, which measures physical, emotional, and cognitive aspects of cancer-related fatigue on a 1-4 scale. Higher scores indicate greater fatigue.
Time frame: single-time point (enrollment)
Psychological distress will be measured using the four-item PHQ-4, including the diagnostic core criteria for depression (PHQ-2) and generalized anxiety disorder (GAD-2), ranging from 1-4. Higher scores indicate greater psychological distress.
Time frame: single-time point (enrollment)
Loneliness will be assessed using the three-item UCLA Loneliness Scale, measuring subjective feelings of loneliness and social isolation, ranging from 1-3. Higher scores indicate greater loneliness.
Time frame: single-time point (enrollment)
Physical complaints will be measured using the EORTC WISP module, allowing participants to report up to three symptoms and rate the degree of burden from 1-4. Higher scores indicate greater impairment due to the respective symptom.
Time frame: single-time point (enrollment)
Communication experiences will be assessed using nine items adapted from the EORTC COMU26 and nine self-developed items, focusing on perceived quality and clarity of communication with healthcare providers. Rated on a 1-4 scale, higher scores indicate greater satisfaction with communication.
Time frame: single-time point (enrollment)
Information sources will be assessed using nine self-developed items, asking participants where they obtain cancer-related information. Response options include two types of "No" (not known or known but not used) and, if "Yes," a rating from 1-3 indicating how helpful the source was, with higher scores reflecting greater helpfulness.
Time frame: single-time point (enrollment)
Sociodemographic characteristics, including age, sex, and migration background will be collected.
Time frame: single-time point (enrollment)
Socioeconomic status will be assessed through items measuring i.a. education, employment status, and income.
Time frame: single-time point (enrollment)
Physical activity will be measured using an adapted version of the Godin-Shephard Leisure-Time Physical Activity Questionnaire. This 4-item questionnaire evaluates the frequency and duration of mild, moderate and vigorous aerobic activities, as well as moderate-to-vigorous strength training, performed during the week. Scores reflect whether participants meet exercise guidelines:
Time frame: single-time point (enrollment)
Information on comorbid conditions (e.g., cardiovascular disease, diabetes, depression) will be collected, capturing co-existing health conditions. The total number of comorbidities will be summed and used as a control variable in the analyses.
Contact information is provided by the study sponsor or research team.
Patricia Blickle, M. Sc.
CONTACT
Tanja Strukelj, M. A.
CONTACT
Technische Universität Dresden
Other
Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)
Acronym: PROSa+
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01109394
Endocrine Tumors, Eye Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06910657
Adenocarcinoma, Adnexal Diseases
St Louis, Missouri, United States
View Trial DetailsNCT07059884
Adnexal Diseases, Anal Cancer
Dublin, California, United States
View Trial DetailsNCT07054944
Germ Cell Tumor, Myosarcoma
Rochester, New York, United States
View Trial Details